Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study
Authors:
- 7 June 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 44 (2) , 161-168
Abstract
Background The skin is the most common organ involved in acute graft‐versus‐host disease (GvHD). Because histopathology has limited utility in ruling out clinical mimics of acute skin GvHD, more accurate diagnostic techniques are required. Aim To evaluate the utility of elafin expression in skin by immunohistochemistry (IHC) for accurate diagnosis of acute skin GvHD. Methods Consecutive allogeneic haematopoietic stem cell transplant (HSCT) recipients during a 6‐month period who developed rash within the first 100 days post‐transplant were recruited. Skin biopsies were taken on the day the rash developed. IHC for epidermal elafin was performed and interpreted by a pathologist blinded to the histopathological diagnosis. Staining of ≥ 50% of epidermis was considered positive. Final diagnosis of the rash was assigned using clinical features supported by histopathology. The accuracy of elafin IHC in predicting the final diagnosis of acute GvHD was evaluated. Results In total, 23 patients (20 male, 3 female; median age 16 years, range 3–53 years) with 27 episodes of skin rash were recruited. Skin rash post‐HSCT occurred at a median of 20 days (range 5–45 days). A diagnosis of GvHD was made in 16 episodes (59.26%) while the remaining 11 episodes (40.74%) were judged to be non‐GvHD rash. Elafin IHC was positive in all patients with GvHD. Of the 11 episodes of non‐GvHD rash, elafin was negative in 8. Thus, the sensitivity and specificity of elafin IHC for predicting acute skin GvHD was 100% and 75%, respectively. Conclusion Tissue elafin is a useful immunohistochemical marker for acute skin GvHD. However, larger studies are needed to validate these results.Keywords
This publication has 22 references indexed in Scilit:
- Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network studyBlood, 2012
- Elafin Is a Biomarker of Graft-Versus-Host Disease of the SkinScience Translational Medicine, 2010
- Graft-versus-host diseaseThe Lancet, 2009
- Cutaneous Graft-versus-Host Disease: A Guide for the DermatologistDermatology, 2008
- Accumulation of Elafin in Actinic Elastosis of Sun-Damaged Skin: Elafin Binds to Elastin and Prevents Elastolytic DegradationJournal of Investigative Dermatology, 2007
- Hyperacute GVHD: risk factors, outcomes, and clinical implicationsBlood, 2006
- High Expression Levels of Keratinocyte Antimicrobial Proteins in Psoriasis Compared with Atopic DermatitisJournal of Investigative Dermatology, 2005
- Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host diseaseJournal of the American Academy of Dermatology, 2004
- Update on Graft versus Host DiseaseJournal of Investigative Dermatology, 2004
- Clinical, Laboratory, and Histopathologic Indicators of the Development of Progressive Acute Graft-Versus-Host DiseaseJournal of Investigative Dermatology, 1992